Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash Flows From Operating Activities
Net (loss) income	$ (8,246)	$ 17,624
Adjustments to reconcile net (loss) income to net cash and cash equivalents provided by operating activities:
Stock-based compensation	22,283	15,031
Deferred taxes	(4,383)	(3,394)
Depreciation and amortization	45,131	44,597
Unrealized gain on investment in equity securities	(8,298)	0
Non-cash operating lease expense	1,134	888
Non-cash interest	319	2,970
Contingent consideration fair value adjustment	1,274	(559)
Gain on sale of building	(5,347)	0
Loss on extinguishment of debt	(7,468)	0
Amortization of inventory step up	3,224	0
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable, net	4,426	(13,404)
Inventories	(20,612)	(1,236)
Prepaid expenses and other assets	3,822	(636)
Accounts payable	7,300	4,772
Accrued royalties	7,171	(2,668)
Prepaid income taxes	(14,268)	4,426
Accrued government rebates	(1,475)	(51)
Returned goods reserve	4,296	(1,961)
Accrued expenses, accrued compensation, and other	2,938	7,820
Net Cash and Cash Equivalents Provided by Operating Activities	48,157	74,219
Cash Flows From Investing Activities
Acquisition of Alimera, net of cash acquired	(393,079)	0
Acquisition of product rights, intangible assets, and other related assets	(631)	(7,143)
Acquisition of property and equipment, net	(13,842)	(6,589)
Proceeds from the sale of building	13,514	0
Net Cash and Cash Equivalents Used in Investing Activities	(394,038)	(13,732)
Cash Flows From Financing Activities
Proceeds from convertible notes	316,250	0
Proceeds from term loan	325,000	0
Purchase of capped call transaction	(40,575)	0
Repayment on borrowings under credit agreement	(292,500)	0
Debt issuance costs	(15,376)	0
Principal payments on borrowings under credit agreements	(1,500)	(2,250)
Series A convertible preferred stock dividends paid	(1,219)	(1,219)
Proceeds from stock option exercises and ESPP purchases	4,788	7,027
Proceeds from public offering	0	80,555
Treasury stock purchases for restricted stock vests	(10,641)	(4,756)
Payments on contingent consideration	(12,500)	0
Payment of accrued licensor payments	(1,875)	0
Net Cash and Cash Equivalents Provided by Financing Activities	269,852	79,357
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	(75)	0
Net Change in Cash, Cash Equivalents, and Restricted Cash	(76,104)	139,844
Cash, cash equivalents, and restricted cash, beginning of period	221,121	53,234
Cash. cash equivalents, and restricted cash end of period	145,017	193,078
Supplemental disclosure for cash flow information:
Cash paid for interest, net of amounts capitalized	19,232	23,426
Cash paid for income taxes	17,214	930
Right-of-use assets obtained in exchange for lease obligations	0	4,499
Supplemental non-cash investing and financing activities:
Property and equipment purchased and included in accounts payable	635	247
Purchase consideration for Alimera Acquisition	(16,523)	0
Accrued deferred financing costs	$ (1,976)	$ 0